Business Wire03.11.19
iSchemaView, a worldwide developer of advanced imaging technology for stroke, has announced significant upgrades to the RAPID APP as well as other messaging and notification capabilities. In its latest release, the world’s most powerful and feature-rich neuroimaging software, RAPID, now includes additional customization of notifications for hospitals and physicians. It also incorporates support to customize the delivery of critical Personal Health Information (PHI) and of RAPID’s latest indication for thrombectomy.
Developed by leading stroke experts, the RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. Together these provide unparalleled sensitivity and specificity across stroke modules (CT perfusion, MR diffusion and perfusion, CTA and CT ASPECT scoring). Results are then delivered by the RAPID Intelligence Services Platform via PACS, email, text, the RAPID APP or corporate partner workflow systems.
“The latest updates to RAPID’s powerful mobile capabilities provide critical convenience and functionality for all of our users,” said Anil Singhal, M.D., iSchemaView senior vice president of Worldwide Operations. “The enhanced RAPID Intelligent Services Platform enables stroke specialists and their teams to communicate with a speed and accuracy that can improve outcomes for stroke patients in what is always a time-sensitive environment.”
New mobile enhancements to the RAPID Intelligent Services Platform include:
Installed in over 1,000 stroke centers, iSchemaView’s RAPID (automated CTP, MR, CTA and ASPECTS), with enhanced AI framework, is the most advanced stroke imaging platform. In clinical trials, RAPID has been shown to aid in the selection of patients in early and late-window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and EXTEND. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, these studies led to new American Heart Association and American Stroke Association guidelines and have dramatically altered the management of acute stroke around the world.
Developed by leading stroke experts, the RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. Together these provide unparalleled sensitivity and specificity across stroke modules (CT perfusion, MR diffusion and perfusion, CTA and CT ASPECT scoring). Results are then delivered by the RAPID Intelligence Services Platform via PACS, email, text, the RAPID APP or corporate partner workflow systems.
“The latest updates to RAPID’s powerful mobile capabilities provide critical convenience and functionality for all of our users,” said Anil Singhal, M.D., iSchemaView senior vice president of Worldwide Operations. “The enhanced RAPID Intelligent Services Platform enables stroke specialists and their teams to communicate with a speed and accuracy that can improve outcomes for stroke patients in what is always a time-sensitive environment.”
New mobile enhancements to the RAPID Intelligent Services Platform include:
- Custom notifications for any RAPID module—RAPID CTA, RAPID ASPECTS, RAPID CTP and RAPID MRI
- Delivery of the right information to the right people at the right time with notifications customized by hospital, physician or by case
- New options for PHI, offering customized PHI content limits to accommodate local regulations, hospital policies or physician preferences
- Notification support of RAPID’s additional U.S. Food and Drug Administration clearance regarding thrombectomy—the new clearance notes that RAPID CT-Perfusion and RAPID MR-Perfusion can be used by physicians to aid in the selection of acute stroke patients with known occlusion of the internal carotid artery or proximal middle cerebral artery for a clot removal procedure; RAPID is the only imaging platform approved for selecting stroke patients for clot removal
- Updated release of the RAPID APP on both Apple iOS and Android platforms
Installed in over 1,000 stroke centers, iSchemaView’s RAPID (automated CTP, MR, CTA and ASPECTS), with enhanced AI framework, is the most advanced stroke imaging platform. In clinical trials, RAPID has been shown to aid in the selection of patients in early and late-window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and EXTEND. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, these studies led to new American Heart Association and American Stroke Association guidelines and have dramatically altered the management of acute stroke around the world.